| 1RV1 |
2.3 |
CRYSTAL STRUCTURE OF HUMAN MDM2 WITH AN IMIDAZOLINE INHIBITOR |
| 1T4E |
2.6 |
Structure of Human MDM2 in complex with a Benzodiazepine Inhibitor |
| 1T4F |
1.9 |
Structure of human MDM2 in complex with an optimized p53 peptide |
| 1YCR |
2.6 |
MDM2 BOUND TO THE TRANSACTIVATION DOMAIN OF P53 |
| 1Z1M |
|
NMR structure of unliganded MDM2 |
| 2AXI |
1.4 |
HDM2 in complex with a beta-hairpin |
| 2C6A |
|
Solution structure of the C4 zinc-finger domain of HDM2 |
| 2C6B |
|
Solution structure of the C4 zinc-finger domain of HDM2 |
| 2F1Y |
1.7 |
Crystal structure of the TRAF-like domain of HAUSP/USP7 bound to a MDM2 peptide |
| 2FOP |
2.1 |
The Crystal Structure of the N-terminal domain of HAUSP/USP7 complexed with mdm2 peptide 147-150 |
| 2GV2 |
1.8 |
MDM2 in complex with an 8-mer p53 peptide analogue |
| 2HDP |
|
Solution Structure of Hdm2 RING Finger Domain |
| 2LZG |
|
NMR Structure of Mdm2 (6-125) with Pip-1 |
| 2M86 |
|
Solution structure of Hdm2 with engineered cyclotide |
| 2MPS |
|
Structure of complex of MDM2(3-109) and P73 TAD(10-25) |
| 2RUH |
|
Chemical Shift Assignments for MIP and MDM2 in bound state |
| 2VJE |
2.2 |
Crystal Structure of the MDM2-MDMX RING Domain Heterodimer |
| 2VJF |
2.3 |
Crystal Structure of the MDM2-MDMX RING Domain Heterodimer |
| 3EQS |
1.65 |
Crystal structure of human MDM2 in complex with a 12-mer peptide inhibitor |
| 3G03 |
1.8 |
Structure of human MDM2 in complex with high affinity peptide |
| 3IUX |
1.65 |
Crystal structure of human MDM2 in complex with a potent miniature protein inhibitor (18-residues) |
| 3IWY |
1.93 |
Crystal structure of human MDM2 complexed with D-peptide (12 residues) |
| 3JZK |
2.1 |
crystal structure of MDM2 with chromenotriazolopyrimidine 1 |
| 3JZR |
2.1 |
Human MDM2 liganded with a 12mer peptide inhibitor (pDI6W) |
| 3JZS |
1.78 |
Human MDM2 liganded with a 12mer peptide inhibitor (pDIQ) |
| 3LBK |
2.3 |
Structure of human MDM2 protein in complex with a small molecule inhibitor |
| 3LBL |
1.6 |
Structure of human MDM2 protein in complex with Mi-63-analog |
| 3LNJ |
2.4 |
Crystal structure of human MDM2 in complex with D-peptide inhibitor (DPMI-alpha) |
| 3LNZ |
1.95 |
Crystal structure of human MDM2 with a 12-mer peptide inhibitor PMI (N8A mutant) |
| 3MQS |
2.4 |
Crystal Structure of the USP7:Hdm2(PSTS) complex |
| 3TJ2 |
2.1 |
Structure of a novel submicromolar MDM2 inhibitor |
| 3TPX |
1.8 |
Crystal structure of human MDM2 in complex with a trifluoromethylated D-peptide inhibitor |
| 3TU1 |
1.603 |
Exhaustive Fluorine Scanning towards Potent p53-MDM2 Antagonist |
| 3V3B |
2.0 |
Structure of the Stapled p53 Peptide Bound to Mdm2 |
| 3VBG |
2.8 |
Structure of hDM2 with Dimer Inducing Indolyl Hydantoin RO-2443 |
| 3VZV |
2.8 |
Crystal structure of human mdm2 with a dihydroimidazothiazole inhibitor |
| 3W69 |
1.9 |
Crystal structure of human mdm2 with a dihydroimidazothiazole inhibitor |
| 4DIJ |
1.9 |
The Central Valine Concept Provides an Entry in a New Class of Non Peptide Inhibitors of the P53-MDM2 Interaction |
| 4ERE |
1.8 |
crystal structure of MDM2 (17-111) in complex with compound 23 |
| 4ERF |
2.0 |
crystal structure of MDM2 (17-111) in complex with compound 29 (AM-8553) |
| 4HBM |
1.9 |
Ordering of the N Terminus of Human MDM2 by Small Molecule Inhibitors |
| 4HFZ |
2.694 |
Crystal Structure of an MDM2/P53 Peptide Complex |
| 4HG7 |
1.6 |
Crystal Structure of an MDM2/Nutlin-3a complex |
| 4JV7 |
2.2 |
Co-crystal structure of MDM2 with inhibitor (2S,5R,6S)-2-benzyl-5,6-bis(4-bromophenyl)-4-methylmorpholin-3-one |
| 4JV9 |
2.5 |
Co-crystal structure of MDM2 with inhibitor (2S,5R,6S)-2-benzyl-5,6-bis(4-chlorophenyl)-4-methylmorpholin-3-one |
| 4JVE |
2.3 |
Co-crystal structure of MDM2 with inhibitor (2R,3E)-2-[(2S,3R,6S)-2,3-bis(4-chlorophenyl)-6-(4-fluorobenzyl)-5-oxomorpholin-4-yl]pent-3-enoic acid |
| 4JVR |
1.7 |
Co-crystal structure of MDM2 with inhibitor (2'S,3R,4'S,5'R)-N-(2-aminoethyl)-6-chloro-4'-(3-chloro-2-fluorophenyl)-2'-(2,2-dimethylpropyl)-2-oxo-1,2-dihydrospiro[indole-3,3'-pyrrolidine]-5'-carboxamide |
| 4JWR |
2.35 |
Co-crystal structure of MDM2 with inhibitor {(2S,5R,6S)-6-(3-chlorophenyl)-5-(4-chlorophenyl)-4-[(2S)-1-hydroxybutan-2-yl]-3-oxomorpholin-2-yl}acetic acid |
| 4MDN |
1.905 |
Structure of a novel submicromolar MDM2 inhibitor |
| 4MDQ |
2.119 |
Structure of a novel submicromolar MDM2 inhibitor |
| 4OAS |
1.7 |
co-crystal structure of MDM2 (17-111) in complex with compound 25 |
| 4OBA |
1.602 |
Co-crystal structure of MDM2 with Inhibitor Compound 4 |
| 4OCC |
1.8 |
co-crystal structure of MDM2(17-111) in complex with compound 48 |
| 4ODE |
1.8 |
Co-Crystal Structure of MDM2 with Inhibitor Compound 4 |
| 4ODF |
2.2006 |
Co-Crystal Structure of MDM2 with Inhibitor Compound 47 |
| 4OGN |
1.377 |
Co-Crystal Structure of MDM2 with Inhbitor Compound 3 |
| 4OGT |
1.5361 |
Co-Crystal Structure of MDM2 with Inhbitor Compound 46 |
| 4OGV |
2.197 |
Co-Crystal Structure of MDM2 with Inhibitor Compound 49 |
| 4OQ3 |
2.3 |
Tetra-substituted imidazoles as a new class of inhibitors of the p53-MDM2 interaction |
| 4QO4 |
1.7 |
co-crystal structure of MDM2 (17-111) with compound 16, {(3R,5R,6S)-5-(3-CHLOROPHENYL)-6-(4-CHLOROPHENYL)-1-[(1S)-1-(6-CYCLOPROPYLPYRIDIN-2-YL)PROPYL]-3-METHYL-2-OXOPIPERIDIN-3-YL}ACETIC ACID |
| 4QOC |
1.7 |
crystal structure of compound 16 bound to MDM2(17-111), {(3R,5R,6S)-5-(3-CHLOROPHENYL)-6-(4-CHLOROPHENYL)-1-[(1S)-1-CYCLOPROPYL-2-(PYRROLIDIN-1-YLSULFONYL)ETHYL]-3-METHYL-2-OXOPIPERIDIN-3-YL}ACETIC ACID |
| 4UD7 |
1.6 |
Structure of the stapled peptide YS-02 bound to MDM2 |
| 4UE1 |
1.45 |
Structure of the stapled peptide YS-01 bound to MDM2 |
| 4UMN |
1.99 |
Structure of a stapled peptide antagonist bound to Nutlin-resistant Mdm2. |
| 4WT2 |
1.42 |
Co-crystal Structure of MDM2 in Complex with AM-7209 |
| 4XXB |
2.4 |
Crystal structure of human MDM2-RPL11 |
| 4ZFI |
2.0 |
Structure of Mdm2 with low molecular weight inhibitor |
| 4ZGK |
2.0 |
Structure of Mdm2 with low molecular weight inhibitor. |
| 4ZYC |
1.95 |
Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding mode: Hdm2 (MDM2) complexed with cpd5 |
| 4ZYF |
1.8 |
Discovery of NVP-CGM097 - a highly potent and selective MDM2 inhibitor undergoing phase 1 clinical trials in p53wt tumors: Hdm2 (MDM2) complexed with NVP-CGM097 |
| 4ZYI |
1.67 |
Discovery of NVP-CGM097 - a highly potent and selective MDM2 inhibitor undergoing phase 1 clinical trials in p53wt tumors: Hdm2 (MDM2) complexed with cpd2 |
| 5AFG |
1.9 |
Structure of the Stapled Peptide Bound to Mdm2 |
| 5C5A |
1.146 |
Crystal Structure of HDM2 in complex with Nutlin-3a |
| 5HMH |
1.79 |
HDM2 in complex with a 3,3-Disubstituted Piperidine |
| 5HMI |
1.74 |
HDM2 in complex with a 3,3-Disubstituted Piperidine |
| 5HMK |
2.17 |
HDM2 in complex with a 3,3-Disubstituted Piperidine |
| 5J7F |
2.0 |
Structure of MDM2 with low molecular weight inhibitor with aliphatic linker. |
| 5J7G |
1.85 |
Structure of MDM2 with low molecular weight inhibitor with aliphatic linker. |
| 5LAV |
1.73 |
Novel Spiro[3H-indole-3,2 -pyrrolidin]-2(1H)-one Inhibitors of the MDM2-p53 Interaction: HDM2 (MDM2) in complex with compound 6b |
| 5LAW |
1.64 |
Novel Spiro[3H-indole-3,2 -pyrrolidin]-2(1H)-one Inhibitors of the MDM2-p53 Interaction: HDM2 (MDM2) IN COMPLEX WITH COMPOUND 14 |
| 5LAY |
2.71 |
Discovery of New Natural-product-inspired Spiro-oxindole Compounds as Orally Active Inhibitors of the MDM2-p53 Interaction: HDM2 (MDM2) IN COMPLEX WITH COMPOUND 6g |
| 5LAZ |
1.66 |
Novel Spiro[3H-indole-3,2 -pyrrolidin]-2(1H)-one Inhibitors of the MDM2-p53 Interaction: HDM2 (MDM2) IN COMPLEX WITH COMPOUND BI-0252 |
| 5LN2 |
1.58 |
Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument |
| 5MNJ |
2.16 |
Structure of MDM2-MDMX-UbcH5B-ubiquitin complex |
| 5OAI |
2.0 |
Structure of MDM2 with low molecular weight inhibitor |
| 5OC8 |
1.56 |
HDM2 (17-111, WILD TYPE) COMPLEXED WITH NVP-HDM201 AT 1.56A |
| 5SWK |
1.923 |
Crystal structure of p53 epitope-scaffold based on a inhibitor of cysteine proteases in complex with human MDM2 |
| 5TRF |
2.1 |
MDM2 in complex with SAR405838 |
| 5UMM |
1.65 |
CRYSTAL STRUCTURE OF HUMAN MDM2 IN COMPLEX WITH 12-MER PEPTIDE INHIBITOR M3 |
| 5VK0 |
1.8 |
Crystal structure of human MDM2 in complex with a 12-mer lysine-cysteine side chain dithiocarbamate stapled peptide inhibitor PMI |
| 5WTS |
3.004 |
Green fluorescent protein linked MTide-02 inhibitor in complex with mdm2 |
| 5XXK |
1.66 |
Structure-activity studies of Mdm2/Mdm4-binding stapled peptides comprising non-natural amino acids |
| 5Z02 |
1.35 |
Crystal structure of HIS6-tagged Mdm2 with nutlin-3a |
| 5ZXF |
1.25 |
The 1.25A Crystal structure of His6-tagged Mdm2 in complex with nutlin-3a |
| 6AAW |
2.0 |
Mdm2 in complex with a D amino Acid Containing Stapled Peptide |
| 6GGN |
2.0 |
In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor |
| 6H22 |
2.006 |
Crystal structure of Mdm2 bound to a stapled peptide |
| 6HFA |
1.79 |
Crystal structure of hDM2 in complex with a C-terminal triurea capped peptide chimera foldamer. |
| 6I29 |
2.1 |
X-ray structure of the p53-MDM2 inhibitor NMI801 bound to HDM2 at 2.1A resolution |
| 6I3S |
1.77 |
Crystal structure of MDM2 in complex with compound 13. |
| 6IM9 |
3.3 |
MDM2 bound CueO-PM2 sensor |
| 6KZU |
1.79 |
Macrocyclization of an all-D linear peptide improves target affinity and imparts cellular activity: A novel stapled alpha-helical peptide modality |
| 6Q96 |
1.8 |
HDM2 (17-111, WILD TYPE) COMPLEXED WITH COMPOUND 12 AT 1.8A; Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes |
| 6Q9H |
2.0 |
HDM2 (17-111, WILD TYPE) COMPLEXED WITH COMPOUND 11 AT 2.0A; Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes |
| 6Q9L |
1.13 |
HDM2 (17-111, WILDTYPE) COMPLEXED WITH COMPOUND 9 AT 1.13A; Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes |
| 6Q9O |
1.21 |
HDM2 (17-111, WILDTYPE) COMPLEXED WITH COMPOUND 10 AT 1.21A; Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes |
| 6SQO |
1.41 |
Crystal structure of human MDM2 RING domain homodimer bound to UbcH5B-Ub |
| 6T2D |
1.8 |
Multicomponent Peptide Stapling as a Diversity-Driven Tool for the Development of Inhibitors of Protein-Protein Interactions |
| 6T2E |
2.4 |
Multicomponent Peptide Stapling as a Diversity-Driven Tool for the Development of Inhibitors of Protein-Protein Interactions |
| 6T2F |
2.09 |
Multicomponent Peptide Stapling as a Diversity-Driven Tool for the Development of Inhibitors of Protein-Protein Interactions |
| 6Y4Q |
1.63 |
Structure of a stapled peptide bound to MDM2 |
| 6YR6 |
1.75 |
14-3-3 sigma in complex with hDM2-186 peptide |
| 7AD0 |
2.07 |
X-ray structure of Mdm2 with modified p53 peptide |
| 7AI0 |
1.559 |
Crystal structure of human MDM2-G443T RING domain homodimer bound to UbcH5B-Ub (Crystal form 1) |
| 7AI1 |
2.07 |
Crystal structure of human MDM2-G443T RING domain homodimer bound to UbcH5B-Ub (Crystal form 2) |
| 7AYE |
2.95 |
Crystal structure of the computationally designed chemically disruptable heterodimer LD6-MDM2 |
| 7BIR |
2.02 |
Inhibitor of MDM2-p53 Interaction |
| 7BIT |
2.13 |
Inhibitor of MDM2-p53 Interaction |
| 7BIV |
1.64 |
Inhibitor of MDM2-p53 Interaction |
| 7BJ0 |
2.0 |
Inhibitor of MDM2-p53 Interaction |
| 7BJ6 |
1.59 |
Inhibitor of MDM2-p53 Interaction |
| 7BMG |
1.83 |
Inhibitor of MDM2-p53 Interaction |
| 7KJM |
1.4 |
CRYSTAL STRUCTURE OF HUMAN MDM2 IN COMPLEX WITH D-PEPTIDE INHIBITOR (DPMI-OMEGA) |
| 7NA1 |
2.3 |
HDM2 in complex with compound 2 |
| 7NA2 |
1.86 |
HDM2 in complex with compound 56 |
| 7NA3 |
2.21 |
HDM2 in complex with compound 62 |
| 7NA4 |
1.84 |
HDM2 in complex with compound 63 |
| 7NUS |
1.45 |
X-RAY STRUCTURE OF HDM2/CMR19 AT 1.45A: Discovery, X-ray structure and CPP-conjugation enabled uptake of p53/MDM2 macrocyclic peptide inhibitors |
| 7QDQ |
1.26 |
Crystal Structure of HDM2 in complex with Caylin-1 |
| 8AEU |
2.0 |
Structure of hMDM2 in complex with Nutlin-3a-aa |
| 8F0Z |
1.61 |
Structure of the MDM2 P53 binding domain in complex with H101, an all-D Helicon Polypeptide |
| 8F10 |
1.28 |
Structure of the MDM2 P53 binding domain in complex with H102, an all-D Helicon Polypeptide |
| 8F12 |
1.86 |
Structure of the MDM2 P53 binding domain in complex with H103, an all-D Helicon Polypeptide |
| 8F13 |
1.4 |
Structure of the MDM2 P53 binding domain in complex with H103, an all-D Helicon Polypeptide, alternative C-terminus |
